Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A mouse model of activating Met mutations.

Carrie R Graveel1, Cheryl A London, George F Vande Woude

  • 1Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.

Cell Cycle (Georgetown, Tex.)
|March 2, 2005
PubMed
Summary

Activating mutations in the Met gene drive unique tumor development in mice. These Met mutations also caused selective gene duplication, mirroring findings in human hereditary papillary renal carcinomas (HPRC).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Impact of preanalytical factors on liquid biopsy in the canine cancer model.

Communications medicine·2026
Same author

Integrated Multiomic Profiling Enhances Risk Stratification and Prognostication in Canine Osteosarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL.

Scientific reports·2026
Same author

Dogs as a Model for Cancer: An Update.

Annual review of animal biosciences·2026
Same author

Multi-omic Longitudinal Analysis of Canine Osteosarcoma Identifies Inter-Patient Heterogeneity and Immune Enrichment in Metastatic Lesions.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Activating mutations in tyrosine kinase Met are implicated in hereditary papillary renal carcinomas (HPRC).
  • The transforming potential of these Met mutations has been previously studied in vitro and in tumor xenografts.

Purpose of the Study:

  • To investigate the in vivo effects of specific Met-activating mutations in the mouse germline.
  • To establish a mouse model for studying Met-driven tumorigenesis and evaluating Met inhibitors.

Main Methods:

  • Generated five mouse lines with targeted mutations in the murine met locus: wild-type (WT), D1226N, Y1228C, M1248T, and M1248T/L1193V.
  • Analyzed tumor profiles and genetic alterations, including allele duplication, in the generated mouse lines.

Main Results:

  • Different mutant Met mouse lines exhibited distinct tumor profiles, including carcinomas, sarcomas, and lymphomas.
  • Observed non-random duplication of the mutant met allele in a majority of tumors from mutant mouse lines, a phenomenon also seen in HPRC patients.
  • Mutations within the kinase domain distinctly affect downstream signaling pathways.

Conclusions:

  • Activating Met mutations are crucial drivers of tumorigenesis with distinct downstream signaling effects.
  • The generated Met mutant mice serve as a valuable model for understanding Met-mediated tumorigenesis and for preclinical testing of Met inhibitors against human cancers with activating Met mutations.

Related Experiment Videos